Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 56

Results For "strategy"

990 News Found

Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation
Digitisation | June 21, 2023

Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation

This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic


Verix acquires start-up.ai
Digitisation | June 21, 2023

Verix acquires start-up.ai

The start-up.ai team will be integrated into Verix, boosting its innovative Life Science AI capabilities


Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
interviews | June 20, 2023

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth


Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
News | June 19, 2023

Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders

Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses


InnoCan submits new patent applications for advanced pain relief technology
News | June 13, 2023

InnoCan submits new patent applications for advanced pain relief technology

The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution


Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
News | June 13, 2023

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor


Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
News | June 12, 2023

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease


Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University
Digitisation | June 09, 2023

Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University

Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration